Pular para o conteúdo principal
Ranking Invest

IDYA - IDEAYA Biosciences, Inc.

Segmento: HealthcareIDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valor de Mercado
$ 3.23 Bi
IVR
0.17Índice proprietário de comparação relativa: 0,17.
IVR2
-0.21Leitura proprietária complementar: -21%.
MLL
-0.21Leitura proprietária complementar: -21%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 1.20 Bi

Dívida Líquida

-$ 272.59 Mi

L4T

-$ 175.02 Mi

MM4T

-678.60%

Indicadores Básicos

ROE

-14.60%

Índices de Previsibilidade

Receita Líquida

G3.41

Lucro

D0.50

Margem

D1.05

Índices de Tendência

Receita Líquida

E-5.45

Lucro

E-4.26

Margem

E-2.72

Índices de Endividamento

DIV/PAT

-0.23

DIV/L4T

1.56

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.